Zinger Key Points
- Windtree Therapeutics shares are trading 40% higher during Wednesday’s pre-market session.
- Sono Group stock is down 5.92% during Wednesday’s pre-market session.
- Get Monthly Picks of Market's Fastest Movers
Benzinga’s “Daily Brief On Trending Tickers” features the top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
Netflix Inc NFLX shares slumped over 27% during Wednesday’s pre-market session after announcing less-than-expected first-quarter revenue and a loss of net paid subscribers.
ASML Holding NV ASML shares are trading 5.97% higher during Wednesday’s pre-market session amid the company's better than expected first-quarter EPS and sales results.
Abbott Laboratories ABT shares are trading 2.68% lower during Wednesday’s pre-market session after reporting better than expected EPS and revenue results.
Procter & Gamble Co PG shares are trading 1.31% higher during Wednesday’s pre-market session after the company reported better than expected EPS and sales growth.
Sono Group NV SEV shares are trading 5.92% lower during Wednesday’s pre-market session due to profit-taking after the company reported its 2021 financial results on Tuesday. The stock jumped over 65% during Tuesday's trading session.
Also Read: No Parallels Between Netflix And Tesla, Says Ark Analyst
Anthem Inc ANTM beat estimated earnings by 5.63%, reporting an EPS of $8.25. At the same time, revenue grew by $5.79 billion over the same period last year, causing shares to move 2.31% higher during Wednesday’s pre-market session.
Lululemon Athletica Inc LULU aims to double its revenue to $12.5 billion by 2026 through its Power of Three ×2 growth strategy, which includes a plan to fold men's and digital revenues and quadruple international revenues relative to 2021.
Windtree Therapeutics Inc WINT shares are trading 40% higher during Wednesday’s pre-market session as the company announced topline results from its phase 2 seismic study of istaroxime in early cardiogenic results.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.